Study seeks to understand impact of investigational treatment on reducing COPD exacerbations in former smokers

A new research study on chronic obstructive pulmonary disease (COPD) is now available in the Greater Houston, Texas, area for a potential treatment for reducing COPD exacerbations. The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD. The study is offered at Care Access locations in Houston, Conroe, Lake Jackson, and Webster.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211259079/en/

(Photo: Business Wire)

COPD, the sixth leading cause of death in the United States, is a serious and life-threatening lung disease that gets worse over time. People with COPD are likely to experience symptom flare-ups, called exacerbations, in which breathing problems worsen and can persist for several days. COPD exacerbations can require hospitalization and are associated with increased mortality. Although COPD is treatable with currently available therapies, there is a need for safer and more effective options.

“COPD can make everyday living very difficult and exacerbations of this disease may be life-threatening,” said Dr. Ali Bajwa, a Care Access Principal Investigator for this study. “This study seeks to better understand how to reduce the risk of exacerbation and help improve the quality of life of those with COPD.”

The research study is now enrolling for former smokers in Greater Houston who are 40 to 85 years old and have been diagnosed with moderate-to-severe COPD. To learn more about this study, visit joincopdstudy.com or contact Care Access at (351) 222-5112.

Care Access opened its doors in the Greater Houston area in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible. The convenient settings throughout the Houston area provide local residents the option to participate in clinical studies close to home.

About Care Access

Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.

To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231211259079/en/

“COPD can make everyday living very difficult and exacerbations of this disease may be life-threatening... This study seeks to better understand how to reduce the risk of exacerbation and help improve the quality of life of those with COPD.” #clinicaltrial